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Abstract
The blood circulation interface and the neural tissue feature unique char-
acteristics encompassed by the term blood -brain barrier (BBB). The barrier’s 
primary functions are maintenance of brain homeostasis, selective transport, and 
protection, all of them determined by its specialized multicellular structure. The 
BBB primarily exists at the level of the brain microvascular endothelium; how-
ever, endothelial cells are not intrinsically capable of forming a barrier. Indeed, 
the development of barrier characteristics in cerebral endothelial cells requires 
coordinated cell–cell interactions and signaling from glial cells (i.e., astrocytes, 
microglia), pericytes, neurons, and extracellular matrix. Such an intricate rela-
tionship implies the existence of a neurovascular unit (NVU). The NVU concept 
emphasizes that the dynamic BBB response to stressors requires coordinated 
interactions between various central nervous system (CNS) cell types and struc-
tures. Every cell type makes an indispensable contribution to the BBBs integrity, 
and any cell’s failure or dysfunction might result in the barrier breakdown, with 
dramatic consequences, such as neuroinflammation and neurodegeneration. This 
chapter will focus on the structure and function of the BBB and discuss how BBB 
breakdown causes detrimental brain function.
Keywords: neurovascular unit, neurovascular coupling, BBB breakdown
1. Introduction
The interface between the blood circulation and the central nervous system 
(CNS) comprises complex multicellular structures with unique features that selec-
tively allow or restrict the passage of substances between these compartments. Two 
distinct blood CNS barriers exist: the endothelial blood-brain barrier (BBB), local-
ized at all levels of the cerebral vascular tree, and the epithelial blood-cerebrospinal 
fluid barrier, situated at the choroid plexuses within the brain’s ventricular system, 
separating the brain interstitial fluid (ISF) and the cerebrospinal fluid (CSF) from 
the peripheral circulation [1].
The BBB is a term used to describe the unique properties of the microvasculature 
of CNS. The vascular tree are continuous non fenestrated vessels and contain a 
series of properties that allow them to tightly regulate the movement of molecules, 
ions, and cells between the blood and the CNS [2, 3]. The human brain is one of 
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the most metabolically active organs in the body, under physiological conditions, 
the human brain receives 20% of the total basal cardiac output and uses 20% of the 
body’s oxygen and glucose [4]. Energy substrates are consumed by the brain from 
the blood via transport across the BBB, as the brain lacks a metabolic reservoir to 
store macromolecules for use when needed. In the mammalian brain, cerebral arter-
ies, arterioles, and capillaries supply CNS with blood in response to neuronal stimuli 
by increasing the rate of cerebral blood flow (CBF), nutrients and oxygen delivery, a 
mechanism known as neurovascular coupling [5].
The neurovascular coupling requires an integrated multicellular response to 
provide the perfusion needs for neuronal metabolism [5], different cell types are 
involved in this action, neurons and astrocytes generate mediators that trigger 
cellular responses in endothelium cells, pericytes, and smooth muscle cells (SMC), 
which contribute to vascular response in the BBB permeability. Functionally, these 
interactions are included in the concept of the neurovascular unit (NVU), which 
comprises various central and peripheral cell types that contribute to BBB structure 
and function (Figure 1) [6, 7]. However, in pathophysiological states, BBB break-
down and dysfunction leads to leakages of harmful blood components into the 
cerebral parenchyma, cellular infiltration, and aberrant transport and clearance 
of molecules [8], which is associated with CBF reductions and dysregulation [9], 
contributing to neurological effects.
Here, we first examine the cellular components that underlie the establish-
ment of the BBB in NVU. Then, we focus on the cellular components of BBB and 
transport physiology. Complementary and in a translational way, examine how 
BBB breakdown and dysfunction related to acute vascular CNS disorders such as 
ischemic and hemorrhagic stroke, and BBB breakdown and dysfunction relate to 
neurological deficits and other pathologies in Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and multiple sclerosis (MS).
Figure 1. 
(A) The multicellular structure of the neurovascular unit (NVU). The BBB is formed by endothelial cells at 
the level of the cerebral bed (arterial and venous). These endothelial cells interact with perivascular elements, 
such as the basal lamina (BMs), smooth muscle cells (SMCs) and astrocytic end-feet processes, perivascular 
neurons and pericytes to form a functional BBB. (B) The core anatomic elements of the NVU. Created with 
BioRender.com.
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2. The BBB and the neurovascular unit
The NVU is a relatively recent neuroscience concept, representing the structural 
and functional multicellular relationship between the brain and blood vessels [5]. 
The cellular components are the endothelial cells (EC), pericytes, perivascular 
astrocytes, microglia, the basement membrane (BM), and neuron (Figure 1) [10]. 
The NVU components share intimate and complex associations, and these associa-
tions have led to their classification as a single functioning unit. The NVU is respon-
sible for the maintenance of a highly selective BBB and cerebral homeostasis, as well 
as the control of CBF [11]. Each NVU component seems to play a specific and active 
role, maintaining the dynamic linkages reciprocally under physiological conditions.
Endothelial cells are considered the BBB’s anatomic basis since they form 
and tightly seal the wall of all cerebral vessels, thereby building a physical barrier 
between the blood and the brain parenchyma (Figure 1). Two different types of 
endothelial junctions exist: adherens junctions (AJ) and tight junctions (TJ) [12]. 
Adherens junctions comprise vascular endothelial (VE) cadherin and neural (N-) 
cadherin, both acting via homophilic interactions [13]. While VE-cadherin is vital 
for sealing adjacent endothelial cells, N-cadherin mediates their association with 
pericytes [13]. TJ contains transmembrane proteins such as claudins, occludins, and 
junction adhesion molecules, as well as the zona occludens cytoplasmic proteins 
(ZO). These proteins act collectively to close off interconnecting endothelial cells 
[14], restricting the paracellular diffusion of hydrophilic substances, even ions; this 
is a unique feature of the BBB endothelium [11] in the other hand, the neurovascu-
lar endothelial cells, in contrast to peripheral endothelial cells, is the low expression 
of adhesion molecules (e.g. member of the immunoglobulin superfamily VCAM-1), 
in this sense, immune cells never cross unstimulated BBB in the healthy CNS [15]. 
Interactions of endothelial cells with other NVU members mediate a decrease in 
transcytotic activity, downregulation of leukocyte adhesion molecules, and regula-
tion of interendothelial junction stability during development and adulthood [14].
Pericytes are mural cells enwrapping capillary blood vessels on their abluminal 
side. Structurally, pericytes extend processes from their cell body, covering several 
endothelial cells (Figure 1). In contrast to peripheral tissues, the brain has the 
highest pericyte to endothelial cell ratio [16]. Pericytes are embedded within the 
basement membrane (BM) of capillary endothelial cells and are thus centrally 
positioned between endothelial cells, astrocytes, and neurons [3]. In total, pericytes 
cover a large cerebral vascular area which can reach up to 40% of the neurovas-
cular surface [17]. One of the main functions of pericytes is the control of the 
vasoreactivity and cerebral blood flow in response to neuronal activity [18]. As a 
recently explored example, glutamate induces prostaglandin E2 and nitric oxide 
release, which leads to actively relaxing pericytes to dilate capillaries [19]. Vascular 
permeability increases with decreasing pericyte coverage, which is partly due to 
the regulation of endothelial transcytosis. Moreover, other parts of the NVU are 
also influenced by pericytes, including neurons, immune cells, and the basement 
membrane [20].
Astrocytes are the most abundant cell type in the brain with a variety of 
functions. Beyond BBB regulation, they participate in synapse formation, 
uptake and recycling of neurotransmitters and ions, regulation of extracellular 
potassium levels, nutrition of neurons, and control of inflammatory responses 
within the CNS [21]. Astrocytes provide a cellular link between the neuronal cir-
cuitry and blood vessels. This neurovascular coupling enables astrocytes to relay 
signals that regulate blood flow in response to neuronal activity; this includes 
regulating the contraction/dilation of vascular SMC surrounding arterioles and 
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capillaries [22, 23]. Astrocytes are also critical cellular support of BBB integrity. 
Recent molecular studies have shown several molecules released by astrocytes 
that enhance and maintain barrier tightness, such as cholesterol and phospho-
lipid transporter molecule apolipoprotein E [24, 25]. Release of apolipoprotein E 
from astrocytes, for example, regulates endothelial TJs by signaling through the 
low-density lipoprotein receptor related protein 1 (LRP1) on both pericytes and 
endothelial cells of CNS microvessels [25]. Astrocytes have been identified as 
essential mediators of BBB formation and function because of purified astro-
cytes’ ability to induce barrier properties in non-CNS blood vessels [26]. Based 
on these observations, it has been proposed that astrocytes are necessary for the 
formation of impermeable TJs in the developing vessels of the BBB.
Microglia derive from hematopoietic precursors that migrate from the yolk sac 
into the CNS parenchyma, acting as the brain’s main line of defense past the BBB 
and play a vital role in innate immune responses in the vascular bed and cerebral 
parenchyma (Figure 1) [27], little is known about how microglial-endothelial com-
munications may shape and regulate the homeostatic BBB. However, studies have 
demonstrated that microglia are associated with endothelial’s nascent vessels in the 
developing brain, and promote the fusion of cells in the stages following vascular 
endothelial growth factor-mediated induction [28]. Recent studies have shown 
the activation of microglia in CNS disorders like AD and multiple sclerosis, which 
are associated with BBB breakdown and neuroinflammation. In these conditions, 
microglial activation may be both a cause and consequence of BBB dysfunction 
[20]. Microglia can exist in one of two active states: in the activated pathway, 
microglia release proinflammatory cytokines like interleukin-1b and tumor necrosis 
factor-a. Whereas in alternative pathways, microglia are involved in tissue repair, 
phagocytosing neurons and foreign material, releasing chemokines and vascular 
endothelial growth factor [29]. On the other hand, brain endothelial cells can also 
secrete molecules that cause microglial activation [30]. In summary, a complex 
interplay between systemic and CNS derived immune cells exists at the BBB.
Basement Membrane: The vascular tube is surrounded by two basement 
membranes (BMs), the inner vascular BM, and the outer parenchymal BM 
(Figure 1). The vascular BM is an extracellular matrix secreted by the ECs and 
pericytes, whereas the parenchymal BM is primarily secreted by astrocytic pro-
cesses that extend towards the vasculature [31]. These BMs consist of different 
molecules, including type IV collagen, laminin, heparin sulfate proteoglycans, and 
other glycoproteins [32]. They provide an anchor for many signaling processes in 
the vasculature and also constitute an additional barrier for molecules and cells 
to cross before accessing the neural tissue. Disruption of these BMs by matrix 
metalloproteinases is an integral part of BBB dysfunction and posterior leukocyte 
infiltration, which can be observed in many different neurological disorders [32].
Neurons and interneurons. Neurons can detect small variations in their supply 
of nutrients and oxygen and transform these signals into electrical and chemi-
cal messages to adjacent interneurons or astrocytes. In response to these signals, 
necessary adjustment mechanisms are initiated. Due to this phenomenon, neurons 
are considered NVU’s pacemaker [15]. Neurons need to be able to signal to cerebral 
vessels when their energy demands change. Positive and negative feedback mecha-
nisms exist to regulate cerebral blood flow, accompanied by adjustments of sub-
strate delivery across the BBB, a process known as neurovascular coupling [33]. In 
this sense, one relevant mechanism for neurovascular coupling is direct innervation 
of astrocytic processes or the endothelial tube by, amongst others, serotonergic, 
noradrenergic, cholinergic, and GABAergic neurons [4]. Mechanisms of neurovas-
cular coupling, particularly those that can explain direct molecular effects on BBB 
integrity, are yet to be established. Future knowledge will be of great interest since 
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new therapeutic tools could help modulate intercellular communication in diseases 
linked to vascular dysfunction.
3. BBB physiology: building blocks and transport routes in BBB
3.1 BBB junctional molecules
The BBB is a diffusion barrier essential for the normal function of the CNS. The 
NVU endothelial cells differ from endothelial cells in the rest of the vascular system 
by their absence of fenestrations, and for having more extensive junctional mol-
ecules, mainly TJ, and sparse pinocytic vesicular transport [34]. These junctional 
molecules limit the paracellular flux of hydrophilic molecules across the BBB. In 
contrast, small lipophilic substances (O2 or CO2) can diffuse freely across plasma 
membranes along their concentration gradient [34]. Nutrients such as glucose and 
amino acids enter the brain via transporters, whereas receptor-mediated endocyto-
sis mediates larger molecules’ uptake, including insulin, leptin, and iron transferrin 
[35], it is believed that all the components of the BBB are essential for the normal 
function, stability, and permeability of the BBB.
The Junction complex in the BBB comprises TJ, AJ, and Gap junctions (GJ). The 
TJ ultrastructurally appear as apparent fusion sites, involving the outer plasma 
membrane of adjacent endothelial cells [36]. The number of TJ strands, as well as 
the frequency of their ramifications, varies and consists of three integral membrane 
proteins: claudin, occludin, and junction adhesion molecules, as well as several 
other cytoplasmic accessory proteins, including members of the family zonula 
occludens (ZO-1, ZO-2, ZO-3) and cingulin (Figure 2). Cytoplasmic proteins link 
membrane proteins to actin, for maintaining the structural and functional integrity 
of the endothelium [36]. The Claudins were identified as the principal component 
of TJ and are localized exclusively at TJ strands. Claudins bind to other claudins 
on adjacent endothelial cells to form the primary seal of the TJ [37]. Closest to the 
Figure 2. 
Basic molecular organization of BBB junctional molecules and transport. The endothelial cells confer unique 
properties on the BBB. They are the principal line of cerebral vasculature and have numerous junctional 
molecules such as tight junctions, adherens junction, gap junctions and accessory proteins that limit the 
passive paracellular diffusion of all but the smallest of solutes and ions. On the other hand, carriers, receptors 
and active efflux protein mediated transport allow substances such as peptides, amino acids, and glucose to 
selectively cross the BBB and release toxic substances and drugs into the blood preventing them from entering the 
brain. Created with BioRender.com.
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apical membrane, the claudin 1, 3, 5, 12, and occludins limit paracellular diffusion 
of solutes and ions across the BBB [38]. Loss of claudins is associated with perme-
ability and BBB breakdown in neurodegenerative disorders and acute CNS diseases 
[39]. TJ proteins connect to actin and vinculin-based cytoskeletal filaments via 
scaffolding proteins of the membrane, associated with ZO 1, 2, and 3 [40]. Previous 
studies have shown that ZO-1 deficiency leads to BBB breakdown in many neu-
rodegenerative and acute CNS disorders [41]. Occludin, another integral protein 
localized at the TJ, form the TJ’s paracellular barrier when conjoined with neigh-
boring cells’ claudins [42]; the cytoplasmic domain of occludin directly associates 
with ZO proteins. The expression of occludin has also been documented in human 
adult brains, but not in average human newborn and fetal brain, suggesting their 
role as regulatory proteins that can alter paracellular permeability of the BBB [35]. 
The third type of TJ-associated membrane protein, junctional adhesion molecules 
(JAM), structurally consists of a single transmembrane domain and an extracellular 
portion with two immunoglobulin-like loops joined by disulfide bonds [43]. Three 
JAM-related proteins, JAM-1, JAM-2, and JAM-3 are expressed in human BBB and 
previous studies have shown their participation in cell-to-cell adhesion and mono-
cyte transmigration through BBB [44].
The AJs are established between neighboring cells by homophilic interac-
tions between the transmembrane proteins, vascular endothelial cadherin 
(VE-cadherin), and epithelial cadherin (E-cadherin) in CNS [13]. Nearby to the 
basolateral membrane, AJ proteins, VE-cadherin, and platelet endothelial cell adhe-
sion molecule (PECAM-1) form homophilic endothelial-to-endothelial contacts 
limit paracellular diffusion of solutes [13]. GJ are other junctional molecules, whose 
connexin-37 (CX37), CX40, and CX43 form hemichannels between endothelial 
cells [45]. These membrane proteins enable direct cytoplasmic exchange of ions and 
low molecular weight metabolites between adjacent cells; these channels of com-
munications are essential for propagating electrical signals and coordination of cell 
signaling by transfer of second messengers [46]. Furthermore, brain endothelial GP 
also support tight junction integrity.
3.2 BBB transport systems
The major BBB transporters, receptors, and channels found in endothelial cells 
and pericytes have been validated by transcriptomic studies and protein analysis 
(Figure 2) [34]. Except for gases and small lipophilic molecules that freely diffuse 
across the endothelium, brain endothelial transport systems regulate molecular 
exchanges between blood and brain. The BBB’s highly selective nature and the high 
metabolic demand of the brain demand other routes of entry for various nutri-
ents to feed and nurture the brain [34]. Metabolic supply is achieved via several 
transporters expressed on the surface of CNS endothelial cells that drive the active 
transport of specific solutes and metabolites into the brain [47]. On the other hand, 
given the close proximity and highly interactive signaling between vascular peri-
cytes and endothelial cells, it is relevant to describe in this chapter the BBB pericyte 
transporter.
Endothelial carrier enables solutes such as carbohydrates, amino acids (AA), 
monocarboxylic acids, hormones, fatty acids, nucleotides, inorganic ions, amines, 
choline, and vitamins to cross the BBB via substrate-specific transporters (Figure 2). 
In terms of carbohydrate transporters, GLUT1 (glucose transporter 1) is a uniporter 
that transports glucose. GLUT1 can transport glucose (and other hexoses) from 
either side of the luminal and abluminal endothelial membrane extracellularly or 
intracellularly [48]. Since glucose is lower in the brain interstitial fluid (ISF) than 
plasma, GLUT1 favors blood-to-brain transport of circulating glucose. GLUT1 is 
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expressed in endothelial cells, but not in neurons. Their importance is best illustrated 
by the fact that transcript encoding GLUT1 is one of the most abundant transcripts 
in brain endothelium. Their dysfunction and lack cause barrier breakdown and can 
prevent clearance of amyloid plaques, suggesting a contributing role in Alzheimer’s 
disease progression [49].
Regarding the transport of amino acids, all essential AA are transported into 
the brain across the BBB via endothelial AA transporter 1 and 2 (LAT1/2), that 
transport bidirectionally neutral AA such as tryptophan and tyrosine [50], and the 
cationic AA transporter 1 and 3 (CAT1/3) that transport cationic AA such as lysine 
and arginine [51]. Also, on the abluminal membrane transporters for excitatory 
AA (EAAT1/2/3) transport glutamate and aspartate out of the brain, limiting 
their excitotoxic effects on neurons [52]. Transporters of neutral and excitatory 
AA, such as glycine, taurine, and GABA are enriched abluminally and with high-
affinity transport from brain to endothelium in a sodium dependent manner, and 
then, these AA are transported across the luminal membrane of the BBB into the 
blood via low-affinity transporters into the circulation [53]. Finally, essential fatty 
acids are essential for brain development and postnatal neural functions. The 
Brain endothelium expresses luminal transporters for fatty acids, including fatty 
acid transport protein 1 and 4 (FATP- 1/4) and the MFSD2A (Major Facilitator 
Superfamily Domain containing 2a) [54]. In the brain, MFSD2a is exclusively 
expressed in brain endothelium and is required for right BBB development and 
functional integrity. Finally, for Lactate released from skeletal muscles during 
exercise, and ketone bodies derived from liver from metabolism of fatty acids, the 
transport is facilitated by monocarboxylate transporter-1 (MCT1). Once inside the 
brain parenchyma, they are used as alternative energy metabolites by the brain, 
supply the brain with key substrates for DNA and RNA synthesis [54]. Nucleotides 
and nitrogenous base, e.g., cytosine, guanine, adenine, thymine and uracil, are 
all transported across the BBB via sodium-independent concentrative nucleoside 
transporter-2 (CNT2) and the sodium-independent equilibrative nucleoside 
transporter-1 and 2 (ENT1/2) [55].
Endothelial receptor is the most important transporter because proteins and 
large macromolecules (e.g., fibrinogen, immunoglobulins, thrombin, plasminogen, 
and growth factors) cannot cross the BBB. However, some proteins and peptides 
use receptor transport to cross the BBB and enter the brain (Figure 2). Transferrin 
receptor (TfR) [56], insulin receptor (IR) [57], and leptin receptor (LEP-R) [58] 
mediate blood-to-brain transport of transferrin (iron-protein carrier), insulin, and 
leptin across the BBB, respectively. This characteristic has promoted its use for CNS 
drug delivery, including therapeutic antibodies [59]. Receptors LRP1 and LRP2 are 
expressed in the BBB’s brain endothelium, with LRP1 binding Alzheimer’s soluble 
Ab fragments and mediating its brain-to-blood clearance [60].
Endothelial active efflux and ion transport. ATP-binding cassette (ABC) 
transporters utilize ATP as an energy source and are expressed at the luminal side 
of the BBB endothelium. They function to prevent brain accumulation of drugs, 
xenobiotics and macromolecules via active efflux from endothelium to blood 
[Figure 2]. Some examples are ABCB1 (also known as P-glycoprotein, P-gp), breast 
cancer resistance protein (BCRP), and multidrug resistance-associated proteins 
(MRP). The BBB also has a significant role in regulating ions’ concentration in the 
CNS. The luminal sodium pump, Na+K+ATPase, is a key regulator of sodium influx 
into the brain and potassium efflux from the brain, maintaining high concentra-
tions of Na+ and low concentrations of K+ in the brain, critical for the electrophysi-
ological equilibrium of the resting membrane and action potentials [61].
Luminal Na-K- Cl (chloride) cotransporter (NKCC) mediates entry of Na+, 
K+ and 2Cl− from blood-to-endothelium. The bicarbonate (HCO3)
−Cl exchanger 
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mediates the entry of intracellular Cl− and the extracellular release of HCO3
−, 
regulating intracellular endothelial pH levels [62]. The Na+-Ca2+ (sodium-calcium) 
exchanger cotransporter mediates Ca2+ efflux from endothelium into brain ISF, 
which maintains low intracellular Ca2+ levels in the microvascular endothelium 
[34]. Abluminal transient receptor potential (TRP) channels, also known as 
non- selective Ca2+ conducting cation channels, are expressed in both arterial 
endothelium and brain microvascular endothelial cell lines. TRP channels regulate 
Ca2 influx into brain endothelium, which in turn promotes the release of soluble 
factors such as NO, prostaglandins, and endothelial-derived hyperpolarizing factor 
initiating endothelium-dependent vasodilation [63]. BBB dysfunction also gener-
ates a leak of molecules across it, enabling considerable vascular fluid movement 
across the microvascular endothelium and the development of vasogenic edema 
[64]. Increased expression and activity of Na-K-Cl cotransporter (NKCC), sodium-
hydrogen antiporter 1 and 2 (NHE1 and NHE2), and TRP channels promote the 
influx of Na+, and Cl−, generating a subsequent gradient osmotical that force the 
water movement across the BBB.
Pericyte transporters. Recent studies suggest that pericytes also express 
several transporters, receptors, and ion channels (Figure 2), such as carbohydrate 
transporters like the insulin-regulated glucose transporter GLUT4 and GLUT10 
[65] and AA transporters, including the high-affinity excitatory AA transporter 
EAAT2, sodium-dependent neutral AA transporter SLC6A17, sodium and chloride 
dependent transporter SLC6A20 for small AA including glycine and proline, GABA 
transporter-1 and 2 (GAT1; GAT2), and the cationic AA transporter CAT2 [34, 65]. 
These transporters contribute to the removal of excitatory AA from the brain to 
prevent excitotoxicity, similar to endothelial transporters.
As endothelial cells, pericytes express lipoprotein receptor LRP1, mediating 
cellular uptake followed by its intracellular degradation and clearance [66] Pericytes 
regulate cerebrovascular integrity in an APOE-dependent way, inhibiting the 
proinflammatory CypA-MMP-9 pathway which prevents the degradation of BBB’s 
TJ and basement membrane proteins [67]. These findings support that pericytes 
play an active role in regulating CBF and permeability of the BBB.
4. BBB dysfunction
BBB’s integrity is essential for the normal functioning of the nervous system. 
It comes as no surprise then that its disruption initiates and perpetuates several 
neurological pathophysiological events. Although the nature and extent of such 
changes vary from every condition, one key commonality is the breakdown of BBB 
and the detrimental functioning of the NVU [4]. The BBB prevents neurotoxic 
plasma components, blood cells, and pathogens from entering the brain (integrity 
of BBB). At the same time, the BBB regulates transport of molecules into and out 
of the central nervous system (CNS) (permeability of BBB). In cerebrovascular 
diseases, BBB breakdown and dysfunction leads to leakages of components into the 
CNS, contributing to neurological deficits [68].
The cells of the NVU are extremely sensitive to a number of different 
substances, including pro-inflammatory cytokines (e.g. IL-1, IL-6, TNF-α, 
interferon-γ), lipid mediators, oxidative compounds (free radical), vasogenic 
agents (e.g. glutamate, serotonin, histamine) and other endogenous stimuli (e.g. 
extracellular K+ and intracellular Ca2+). Many of these substances are released under 
pathophysiological conditions and changes of their levels in BBB is a critical event in 
the development and progression of CNS dysfunction [69]. In some cases, increased 
BBB permeability is a consequence of the pathology, such as with ischemic stroke 
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and traumatic brain injury, increased of intrinsic cellular proinflammatory, oxida-
tive stress and dysregulation of vasogenic mediators, whereas in other cases BBB 
opening may be another condition in which cerebrovascular abnormalities have 
been noted, such as neurodegenerative disease [70]. As a result, there is a direct 
association between integrity impairment and high permeability of these sub-
stances in the brain. Some of the steps that follow include alteration or breakdown 
of the physical, transport, and immune barriers.
4.1 Alteration of BBB by cerebrovascular injury
4.1.1 Ischemic stroke
In ischemic stroke, there is a sudden cessation of blood supply to the brain tissue, 
which translates into reduced oxygen and glucose delivery, both essential for ATP 
production. Depletion of ATP levels can lead to impaired functioning of Na/K-
ATPase and Ca+2ATPase activity, generating ion- gradient failure and abnormal 
intracellular ion accumulation. By contrast, endothelial transporters’ activity, such 
as Na/H ion-exchanger and Na-K-Cl cotransporter are stimulated. This second-
arily induces increased Na+, Cl−, and water across to the barrier and into the brain 
parenchyma, which results in characteristic cytotoxic edema secondary to ischemia 
[71]. The stimulation of this transporter’s activity also triggers endothelial cell Na+ 
accumulation, generating swelling that contributes to BBB breakdown [72]. The Na+ 
cellular uptake depolarizes the cell’s membrane, opening voltage-gated ion chan-
nels and promoting Ca2+ further cell uptake. These changes, in turn, prompt the 
release of excitatory neurotransmitters, which can be toxic [71]. BBB’s breakdown 
in stroke occurs in a biphasic subacute fashion [70]. In the initial hit, activated 
metalloproteinases MMP-2 attack tight junction proteins. This activation is medi-
ated by membrane-type MMP (MMP-14) and the fur gene expression, regulated by 
hypoxia-induced factor 1a (HIF-1a) [73]. Decreased expression and disorganization 
of tight junction constituent proteins, claudins, are the first signs of BBB damage, 
with further dysfunction of influx and efflux BBB transporters’ expression. These 
changes are limit the hypoxic area and revert after the acute insult [70].
After 24 and 48 hours post-reperfusion, a non-reversible second phase takes 
place. Proinflammatory local cytokines activate inducible and freely available 
metalloproteinases MMP-3 and MMP-9, whose destructive activity characterizes 
this phase [74]. The most abundant cytokines present in focal cerebral ischemic 
areas are TNF-alfa and IL-1b [75] and have also been observed to decrease the 
expression of occludin and ZO-1 [76]. Cyclooxygenase-2 also plays a role in this 
second and more harmful opening of the BBB. Although this inflammation is local 
and mainly initiated by the activation of glia and pericytes, the BBB’s damage and 
opening allow monocytes and neutrophils’ entrance, perpetuating and amplifying 
the local inflammatory response [74]. The breakage of BBB in ischemic stroke is 
also the precursor of further complications such as the hemorrhagic transformation 
of the infarcted parenchyma [77]. A schematic view of ischemic stroke and intrace-
rebral hemorrhage mechanisms are shown in Figure 3.
BBB can also be disrupted by the action of reactive oxygen species (ROS) and 
ensuing oxidative stress. Superoxide anion (O2−) is a known mediator of cellular 
damage after ischemic stroke. Under oxidative stress conditions such as stroke, 
superoxide dismutase’s (SOD) metabolic capacity of controlling the biological 
activity of O2− gets surpassed. When combined with nitric oxide (NO), O2− forms 
peroxynitrite, a cytotoxic and proinflammatory molecule that can initiate and 
amplify BBB’s injury by its ability to nitrosylate tyrosine and inducing endothelial 
damage [78]. Oxidative stress plays a critical role in ischemia/reperfusion (I/R) 
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induced brain injury by stroke, various mechanisms in the neurovascular bed 
can trigger oxidative stress, including mitochondrial dysfunction, increase vaso-
genic mediators, glutamate release, and depletion of antioxidant defense system. 
Mitochondria are both important intracellular organelles for energy metabolism 
organelles, the main intracellular source of ROS, and important targets for I/R 
brain injury [79]. During stroke, inflammatory cytokines, oxidative stress, and Ca+2 
overload stimulate the mitochondria, inducing the production of higher ROS levels, 
thereby triggering the mitochondrial necrosis pathway and leading to cell death 
[80]. In addition, endothelial cells, and immune cells produce large amounts of ROS 
during the cerebral ischemia phase, which in turn induce the activation of nuclear 
factor-κappa B (NF-κB), inducible endothelial nitric oxide (iNOS), and proinflam-
matory factors, triggering the upregulation of vascular endothelial cell adhesion 
molecules and causing BBB permeability [81].
4.1.2 Intracerebral hemorraghe
Between 10 and 15% of all strokes in the USA are intracerebral hemorrhages, 
which has higher morbidity and mortality when compared to ischemic strokes. 
Multiple etiologies are associated with ICH, hypertension being the more common, 
followed by amyloid pathology, especially in older populations, vascular malforma-
tions, and coagulopathies [72]. After the initial bleed, there can be a continuous 
bleed for the next 24 hours, the so-called hematoma expansion. A delayed vascular 
disruption occurs after the first 24 hours; this includes BBB dysfunction, which  
can associate with edema formation and an influx of leukocytes into the brain 
parenchyma [82].
The role of ischemia in ICH-induced brain injury is controversial, as a reduction 
in blood flow may be a result rather than the cause of brain damage. This suggests 
that BBB’s increased permeability is due to the direct effect of certain blood com-
ponents (thrombin, fibrin, and hemoglobin, iron) or to the inflammatory response 
to these components [72]. This phenomenon may include further peripheral cell 
Figure 3. 
A schematic view of ischemic stroke and intracerebral hemorrhage mechanisms. Activation of glutamate 
receptors following ischemic stroke leads to excitotoxicity and calcium influx, this impairs the neuronal 
homeostasis leading to activation of several calcium dependent pathways that include proteases and nucleases. 
Reperfusion aggravates the cerebral parenchyma damage by forming free radicals that damage the membranes 
and proteins. Further, the opening of mitochondrial permeability transition pore releases various proapoptotic 
molecules that activate apoptotic cell death in cerebral parenchyma. In intracerebral hemorrhage the initial 
bleed causes physical disruption of the cellular architecture of the brain and the mass of the haematoma may 
increase intracranial pressure which can compress brain regions, increasing neuronal death result of necrotic 
and apoptotic mechanisms depending on the severity of insult. Created with BioRender.com.
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infiltration and microglia activation, which may promote the higher secretion of 
proinflammatory cytokines and the activation of MMPs, as previously described in 
ischemic stroke [83].
4.2 Alteration of BBB by neurological disorders
4.2.1 Alzheimer’s disease
Alzheimer’s disease (AD) pathological hallmark is the accumulation of amyloid 
beta plaque deposits, which suggests the imbalance between its production and 
clearance rates may be due to a leaky BBB. The BBB dysfunction itself can also 
promote and accelerate the process of further AB production [84]. Diminished 
expression and dysfunction of ABC transporters at the BBB have been found in AD 
mice models [85], and two crucial BBB transporters in Abeta BBB’s flow dynamics, 
p-glycoprotein LRP1, and RAGE have been identified as functionally impaired in 
AD. Expression of LRP1, which is in charge of the efflux of brain-derived Ab into 
blood across the BBB, is remarkably low at the BBB in AD patients’ and AD models’ 
brains [86]. Verapamil-PET studies in patients with mild AD, an exam that clinically 
assesses p-glycoprotein function, have found reduced activity of this transport in 
frontal, posterior cingulate, and the parietooccipital cortices, as well as in the hip-
pocampus [87]. RAGE is a vital transporter that regulates the influx of circulating 
soluble ab intro the brain, which may promote neuroinflammation. Patients with 
AD develop increased levels of this transporter receptor both in brain endothelium 
and mural cells of the BBB [88].
There is enough evidence that associates AD with vascular disease at a pathologi-
cal level [89]. Cerebral vessel pathology is not only a significant risk factor for AD 
but can also cause BBB disruption, as is the case with cerebral amyloid angiopathy 
[90]. Furthermore, changes in vascular biomarkers have been observed in preclini-
cal AD before the development of cognitive impairment, and even before increases 
in routine AD biomarkers [91]. These findings support the two-hit vascular hypoth-
esis of AD suggests that BBB dysfunction and brain hypoperfusion secondary to 
blood vessel damage may be the first hit that leads to ab accumulation and neuronal 
injury [92]. There is also evidence that at least two out of three BBB’s main three 
cell lines are significantly compromised in AD. Accelerated pericyte degeneration 
and BBB breakdown is a distinguishing characteristic of AD-ApoE4 carriers mouse 
models [93]. On the other hand, astrocytic dysfunction, which has also been seen in 
AD models [84], may explain the hyperactivity of RAGE and hypoactivity of LRP1 
in these patients’ BBB. The pericyte degeneration initiates multiple pathways of 
neurodegeneration owing to the entry of several neurotoxic blood-derived proteins, 
including plasminogen, thrombin and fibrinogen which enter different areas of the 
CNS [93]. Plasmin, which is generated from circulating plasminogen, degrades the 
neuronal matrix protein laminin, thereby promoting neuronal injury. High concen-
trations of thrombin mediate neurotoxicity and memory impairment and accelerate 
BBB disruption [94].
4.2.2 Parkinson’s disease
PD is one of the most prevalent neurodegenerative diseases after AD. It is 
characterized by filamentous and oligomeric α-synuclein (α-syn) accumulation, 
and degeneration of dopaminergic neurons in the substantia nigra leading to motor 
impairments [34]. Ever since the publication of Braak et al. studies, there is consen-
sus that Parkinson’s disease starts in the peripheral system and reaches the central 
nervous system in a retrograde (axon terminal to soma) spread of Lewy pathology. 
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Some authors have suggested that this spread could be through a hematogenous 
pathway [95]. Although PD patients in Braak stage 1 have their axon terminals out-
side the BBB, this same structure protects the somas of those axons, which reside in 
the central nervous system. Cerebrovascular disease also plays a part in PD, as both 
vascular disease and vascular risk factors aggravate motor and cognitive symptoms 
[96]. This may explain the BBB leakiness observed in these patients, as a recent 
study observed in the post-commissural putamen of PD patients, using histologic 
markers of serum protein, iron, and erythrocyte extravasation [97]. Regarding 
the extravasation of molecules through the cerebral vascular system, the histologi-
cal analysis of PD patients reveals BBB breakdown in the striatum as shown by 
capillary leakages and accumulation of perivascular fibrinogen, immunoglobulins 
deposits, hemosiderin, red blood cells extravasation and leukocyte infiltration [98]. 
Increased BBB permeability and inducing inflammatory and necrotic processes in 
the brain parenchyma.
In patients with PD, a dysregulation of the transport systems has also been 
observed in the BBB, recent studies reveal that α-syn crosses the BBB, which could 
signify an important contributory event in PD pathogenesis (neurodegeneration) 
[99]. The α-syn oligomers crossed the BBB into the brain, in parenchyma where 
α-syn amplification and strain-specific pathology and neurotoxic phenotypes. In 
the other hand, regarding the clearance of the α-syn, this molecule is capable of 
inhibiting Aβ efflux suggesting and the endothelial LRP1 is a only potential efflux 
transporter for α-syn, however, LRP1 is similarly downregulated in PD [100], this 
could result in impaired α-syn BBB clearance and accumulation in brain, suggest-
ing that the high levels of α-syn produced peripherally can enter the brain in the 
presence of BBB breakdown, which may also contribute to development of PD 
pathology.
4.2.3 Multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease with an early BBB disruption 
pattern. One clear indication is the presence of Gadolinium-enhancing lesions on 
magnetic resonance, which translates in extravasation of intravascular contrast 
due to brain parenchyma and its associated active inflammation. Moreover, an 
increasing amount of evidence shows this disruption could not be restricted to 
Gd-enhancing lesions, as observed in non-enhancing areas in postmortem MS 
brains [101]. As the entry of inflammatory infiltrate occurs in the brain’s perivas-
cular regions, it is intuitive to think BBB disruption is very likely an early event in 
lesion formation.
There is also evidence of maladaptive changes in the NVU’s components. One 
great example is ECs, which upregulate adhesion molecules and display chemokines 
on their luminal surface, to promote transcellular immune cell migration [102]. 
Also, in MS, TJ abnormalities can be seen, as one study observed abnormal ZO-1 at 
TJs in sections of primary progressive MS patients’ cortical grey matter [101]. The 
BM in these patients’ lesions also appears discontinuous. MRI studies have shown 
hypoperfusion in early and advanced stages of MS, suggesting the presence of 
metabolic injury in the brain parenchyma in a hypoxia-like fashion [103]. Regarding 
a primary BBB dysfunction, studies have focused on astrocytes and pericytes, 
whose maladaptive changes could explain the reduction in capillary blood flow and 
further hypoxia. D’haeseleer et al. observed that the hypoperfusion in MS could be 
mediated by astrocyte’s released endothelin-1 (ET-1), as it can be normalized with 
an ET-1 antagonist [104]. This body of evidence conveys heterogeneous pathophysi-
ology in MS, one that included BBB breakdown as a primary event and not only as a 
secondary consequence [105].
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5. Conclusion and future directions
The relevance of the NVU in the support of cerebral homeostasis of the BBB 
is being partly established with recent evidence. The multifactorial interactions 
between their components are extremely refined, expressing the complexity of 
the central CNS physiology. The knowledge of each of the components and their 
respective pathways are critical to understanding various neurovascular diseases, 
such as cerebrovascular injury (e.g. stroke) and neurological disorders (e.g. 
Alzheimer’s). Although despite current knowledge, many questions about the role 
of each component NVU, pathways and crosstalking still have no answer. These 
advances have uncovered gaps in our knowledge of neurovascular health and have 
provided us with the roadmap to ask new questions that should be addressed by 
the future studies. Finally, based on the current state of our knowledge, it is prob-
ably time to think about BBB not only as an impermeable cellular membrane which 
protects brain from peripheral influences and should be breached for therapeutic 
CNS drug delivery, but also as an enormous source of understudied molecular and 
cellular targets in the pathophysiological states, which if explored could change 
the paradigm about brain diseases therapy and could lead to development of novel 
BBB-based personalized approaches to treat them.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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